Spire Healthcare Group plc (LON:SPI - Get Free Report)'s share price rose 14.1% during mid-day trading on Friday . The stock traded as high as GBX 256.50 ($3.46) and last traded at GBX 247 ($3.33). Approximately 9,747,062 shares were traded during trading, an increase of 563% from the average daily volume of 1,469,073 shares. The stock had previously closed at GBX 216.50 ($2.92).
Wall Street Analysts Forecast Growth
SPI has been the subject of several recent analyst reports. Berenberg Bank restated a "buy" rating and set a GBX 280 price objective on shares of Spire Healthcare Group in a research report on Thursday, July 31st. JPMorgan Chase & Co. lowered their price objective on shares of Spire Healthcare Group from GBX 309 to GBX 303 and set an "overweight" rating for the company in a research note on Tuesday, August 5th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of GBX 294.33.
Read Our Latest Research Report on Spire Healthcare Group
Spire Healthcare Group Trading Up 14.1%
The business's fifty day simple moving average is GBX 218.75 and its two-hundred day simple moving average is GBX 203.41. The company has a market cap of £993.86 million, a price-to-earnings ratio of 5,369.57, a PEG ratio of 1.06 and a beta of 0.96. The company has a quick ratio of 0.74, a current ratio of 0.70 and a debt-to-equity ratio of 62.25.
Spire Healthcare Group (LON:SPI - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported GBX 4.10 EPS for the quarter. Spire Healthcare Group had a net margin of 1.96% and a return on equity of 3.82%. On average, equities analysts predict that Spire Healthcare Group plc will post 15.6634747 EPS for the current year.
Spire Healthcare Group Company Profile
(
Get Free Report)
Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.
Further Reading
Before you consider Spire Healthcare Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spire Healthcare Group wasn't on the list.
While Spire Healthcare Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.